We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
101
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.24M 0.2%
50,101
-14,398
-22% -$1.61M
QURE icon
102
uniQure
QURE
$2.93B
$5.1M 0.19%
71,191
+27,342
+62% +$1.5M
XNCR icon
103
Xencor
XNCR
$1.59B
$5.1M 0.19%
148,231
– –
SNN icon
104
Smith & Nephew
SNN
$13.6B
$4.79M 0.18%
99,560
-22,085
-18% -$997K
PTCT icon
105
PTC Therapeutics
PTCT
$6.26B
$4.77M 0.18%
99,327
-49,108
-33% -$2.09M
UTHR icon
106
United Therapeutics
UTHR
$26.2B
$4.76M 0.18%
54,094
– –
RCKT icon
107
Rocket Pharmaceuticals
RCKT
$351M
$4.72M 0.18%
207,555
– –
IBB icon
108
iShares Biotechnology ETF
IBB
$9.52B
$4.68M 0.18%
38,834
+19,920
+105% +$2.22M
CRSP icon
109
CRISPR Therapeutics
CRSP
$4.77B
$4.64M 0.18%
76,222
-25,114
-25% -$1.37M
XLRN
110
DELISTED
Acceleron Pharma
XLRN
$4.58M 0.17%
86,313
– –
ARDX icon
111
Ardelyx
ARDX
$1.25B
$4.56M 0.17%
607,698
+25,000
+4% +$152K
ACHC icon
112
Acadia Healthcare
ACHC
$2.62B
$4.53M 0.17%
136,200
– –
BMY.RT
113
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$4.44M 0.17%
+1,473,710
New +$3.83M
DOC icon
114
Healthpeak Properties
DOC
$15.2B
$4.43M 0.17%
128,537
+83,037
+182% +$2.91M
ARQL
115
DELISTED
Arqule Inc
ARQL
$4.4M 0.17%
220,409
+144,355
+190% +$1.67M
EDIT icon
116
Editas Medicine
EDIT
$413M
$4.38M 0.17%
147,939
– –
THC icon
117
Tenet Healthcare
THC
$21.8B
$4.31M 0.16%
113,436
-27,700
-20% -$830K
RMD icon
118
ResMed
RMD
$30.3B
$4.3M 0.16%
27,775
-9,335
-25% -$1.35M
LGND icon
119
Ligand Pharmaceuticals
LGND
$5.94B
$4.27M 0.16%
65,651
-4,969
-7% -$332K
ICPT
120
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.26M 0.16%
34,414
– –
RARE icon
121
Ultragenyx Pharmaceutical
RARE
$2.56B
$4.16M 0.16%
97,480
– –
BHC icon
122
Bausch Health
BHC
$2.25B
$4.15M 0.16%
138,812
-30,000
-18% -$780K
TAK icon
123
Takeda Pharmaceutical
TAK
$55.1B
$4.15M 0.16%
210,146
– –
ALKS icon
124
Alkermes
ALKS
$8.39B
$4.04M 0.15%
198,048
– –
APLS
125
DELISTED
Apellis Pharmaceuticals
APLS
$4.01M 0.15%
130,999
+32,215
+33% +$892K
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.